TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management Commentary: “Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business. We are pleased with the impact of our medical affairs initiatives and the strengthened engagement within the Canadian medical community, which have contributed to consecutive quarters of revenue growth in Canada. We also continued to translate our scientific leadership into tangible value through new IP and global collaborations. Despite short-term margin pressures, we remain confident...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — “This quarter, we delivered strong net earnings that reflected the first full quarter of royalty revenue from the Borborema Gold Project and substantial investment gains across our mining portfolio.”, said Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation. “With recurring cash flow now beginning to support our core cost base, we are in a stronger position to redeploy capital toward growth – reinforcing our ability to deliver sustained shareholder value.” “The announced acquisition of Maritime Resources by New Found Gold marks another pivotal validation of our long-term investment strategy.” Mr. Goodman continued. “We recognized the intrinsic value of Maritime early and supported the company through market cycles. The transaction highlights our ability to identify...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus  Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation programs IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent business highlights. “The results from our Phase 2 BESTOW trial demonstrated tegoprubart’s excellent efficacy and safety, importantly avoiding many of the long-term toxicities commonly seen with current standard-of-care...

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy (OMPD) registrational program and associated regulatory filing activities– HAYWARD, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma...

Increased Profits in the Third Quarter 2025 SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp (OTCMTS: OMQS or “omniQ” or “the Company”) today announced its financial results for the third quarter 2025. The company reported $8.8 million in revenue and $3 million gross profit. The company continues to implement its cost-reduction strategy designed to strengthen profitability and support long-term operational efficiency. Financial HighlightsRevenue: $8.8 million compared to $9.5 million year-over-year. This was attributable to the focus on more profitable revenue and the timing of some orders. Gross Profit: $3 million compared to $2 million in the three-month period for 2024. Loss from Operations: $591 thousand compared to $787 thousand year-over-year. This represents a 13.7% improvement. Continued to focus on operational...

SAN JOSE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended September 30, 2025. As of September 30, 2025, the Fund’s net assets were $296,547, or $0.04 per share, compared with net assets of approximately $0.7 million, or $0.11 per share as of June 30, 2025. As of September 30, 2025, the Fund’s portfolio included public and private securities valued at $256,934, or $0.04 per share, which includes approximately $0.01 per share in cash and cash equivalents. Portfolio Summary (as of 9/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $197,925 $0.03Cash/Cash Equivalents $59,009 $0.01Other...

Second quarter results highlight improved cost management capital structure enhancements DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 second quarter, which ended September 30, 2025. Commenting on the fiscal 2026 second quarter results, interim Chief Executive Officer James Silk said: “The second quarter results demonstrate our disciplined approach to managing both our investment portfolio and operating expenses during a pivotal period for Beneficient. We reduced expenses, completed new primary capital transactions, generated additional liquidity through asset sales...

Total Revenue of $77.7 million, an increase of approximately 15% quarter-over-quarter Net Income of $1.3 million Record Adjusted EBITDA of $56.3 million, an increase of over 45% quarter-over-quarter Approximately 10% increase in quarterly production to a total of 23,029 Boe/d per day (52% oil / 72% liquids) Current production rate of approximately 27,000 net Boe/d per dayHOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our,” or “us”) – an independent energy company engaged in the development and acquisition of oil, natural gas, and natural gas liquids (“NGL”) resources in the Denver-Julesburg (DJ) Basin – today announced its financial and operational results through and subsequent to the quarter ended September 30, 2025. RECENT KEY HIGHLIGHTSRecord total production...

Company to host investor conference call and webcast on Monday, November 17th, at 9:00am EST PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights:Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional...

CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) (TSX:PPR) announces its financial and operating results for the third quarter of 2025. The Company’s interim financial statements for the three and nine months ended September 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca. THIRD QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTSProduction averaged 2,295 boe/d (57% liquids)1 for Q3 2025, which was 6% or 122 boe/d higher than Q3 2024, due to the increased Basal Quartz production. Q3 2025 operating expenses were $30.39 boe/d, an increase of 13% or $3.46 per boe/d from Q3 2024, principally due to higher spending with respect to chemicals,...